Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4839-4847

  Neal, Zane C ^a   Yang, Jeannie C ^a   Rakhmilevich, Alexander L ^a   Buhtoiarov, Ilia N ^a   Lum, Hillary E ^a   Imboden, Michael ^b   Hank, Jacquelyn A ^a   Lode, Holger N ^c   Reisfeld, Ralph A ^d   Gillies, Stephen D ^e   Sondel, Paul M ^a,f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b IoGenetics   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e EMD SERONO INC   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HU14 18 INTERLEUKIN 2 FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROTEIN HU14 18; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; LIVER METASTASIS; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GANGLIOSIDES; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NEOPLASM METASTASIS; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; SPLEEN; TIME FACTORS;

EID: 3242731107     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0799     Document Type: Article

References (40)

1. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998;80:277-92.
2. Reisfeld RA. Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Pigment Cell Res 1992;109-12.
3. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992;89:1428-32.
4. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992;3:19-24.
5. Sondel PM, Gillies SD. Immunocytokines for Cancer Immunotherapy. In: Morse MA, Clay TM, Lyerly HK, editor. Handbook of cancer vaccines. Totowa, NJ: Humana Press, Inc.; 2003. p. 341-57.
6. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15.
7. Neal ZC, Imboden M, Rakhmilevich AL, et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 2004;53:41-52.
8. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst (Bethesda) 1997;89:1586-94.
9. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001;7:2862-9.
10. Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 1999;96:8591-6.
11. Lode HN, Moehler T, Xiang R, et al. Synergy between an anti-angiogenic integrin alpha, antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999;96:1591-6.
12. Greene LA, Shain W, Chalazonitis A, et al. Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. Proc Natl Acad Sci USA 1975;72:4923-7.
13. Hank JA, Surfus JE, Gan JC, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD(2) interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 1996;2:1951-9.
14. Imboden M, Murphy KR, Rakhmilevich AL, et al. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001;61:1500-7.
15. Turner JG, Rakhmilevich AL, Burdelya C, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 2001;166:89-94.
16. Yron I, Erlich R, Efrati M, Shohat L, Witz IP, Sahar E. Comparison of NK activity in mouse spleen and peripheral blood lymphocytes. Immunobiology 1988;177:449-59.
17. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell-mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 1990;50:5234-9.
18. Chang AE, Hyatt CL, Rosenberg SA. Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Mod 1984;3:561-72.
19. Hank JA, Surfus J, Gan J, et al. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res 1999;5:281-9.
20. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-7.
21. -- mice. J Immunol 1996;157:2366-73.
22. Kendra K, Gan J, Ricci M, et al. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 1999;48:219-29.
23. Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50:2009-17.
24. Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986;4:1380-91.
25. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994;27:19-31.
26. Albertini MR, Gan J, Jaeger P, et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother 1996;19:278-95.
27. Hank JA, Albertini MR, Gan J, et al. Clinical administration of antibody-cytokine hu14.18-IL2 induces IL-2-mediated immune activation. Proc Am Assoc Cancer Res 2003;44:1326.
28. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T-cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998;95:2475-80. Erratum in: Proc Natl Acad Sci USA 2000;977:3782.
29. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T-cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998;95:2475-80. Erratum in: Proc Natl Acad Sci USA 2000;977:3782.
30. Pertl U, Luster AD, Varki NM, et al. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T-cell response induced by single-chain IL-12 gene therapy. J Immunol 2001;166:6944-51.
31. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 2000;35:641-6.
32. Peril U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 2003;101:649-54.
33. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T-cell memory by NK-cell-mediated tumor rejection. Nat Immunol 2002;3:83-90.
34. Kurosawa S, Harada M, Matsuzaki G, et al. Early-appearing tumor-infiltrating natural-killer-cells play a crucial role in the generation of antitumor T lymphocytes. Immunology 1995;85:338-46.
35. Steinstreilein J, Witte PL, Streilein JW, Guffee J. Local cellular defenses in influenza-infected lungs. Cell Immunol 1985;95:234-46.
36. Skoner DP, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P. Effect of influenza A virus infection on natural and adaptive cellular immunity. Clin Immunol Immunopathol 1996;79:294-302.
37. Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J 2003;22:2546-51.
38. Lu P, Sharom FJ. Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low-protein environment. Immunology 1995;86:356-63.
39. Chu JWK, Sharom FJ. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell-surface receptors. Immunology 1993;79:10-7.
40. Lu P, Sharom FJ. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides. Cell Immunol 1996;173:22-32.